Show
Sort by
-
- Journal Article
- A1
- open access
A plain language summary of publication of the efficacy and safety of individualized niraparib dosing based on baseline body weight and platelet count in the PRIMA/ENGOT-OV26/GOG-3012 trial
-
Cancer staff in an NHS cancer center : infections, vaccination, stress and well-being support during the COVID-19 pandemic
-
- Miscellaneous
- open access
Many people with chronic lymphocytic leukemia or small lymphocytic lymphoma benefit from Ibrutinib treatment up to 8 years : a plain language summary
-
ROSALINE : a phase II, neoadjuvant study targeting ROS1 in combination with endocrine therapy in invasive lobular carcinoma of the breast
-
- Journal Article
- A1
- open access
Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma
-
The importance of patient and public involvement in cancer research : time to create a new job profile
-
Phase II open-label study investigating apalutamide in patients with biochemical progression after radical prostatectomy
-
A case report and a literature review of primary retroperitoneal mucinous cystadenoma : the importance of imaging in diagnosis and management
-
REACT expanded-access program in patients with metastatic renal cell carcinoma : real-world data from a European subanalysis
-
Rituximab: modes of action, remaining dispute and future perspective